[go: up one dir, main page]

HK1212389A1 - Carbonic anhydrase ix-related markers and use thereof - Google Patents

Carbonic anhydrase ix-related markers and use thereof Download PDF

Info

Publication number
HK1212389A1
HK1212389A1 HK15102061.3A HK15102061A HK1212389A1 HK 1212389 A1 HK1212389 A1 HK 1212389A1 HK 15102061 A HK15102061 A HK 15102061A HK 1212389 A1 HK1212389 A1 HK 1212389A1
Authority
HK
Hong Kong
Prior art keywords
cancer
carbonic anhydrase
detecting
related markers
methods
Prior art date
Application number
HK15102061.3A
Other languages
English (en)
Chinese (zh)
Inventor
C. Mcdonald Paul
E. Lock Frances
Dedhar Shoukat
Original Assignee
Signalchem Lifesciences Corporation
British Columbia Cancer Agency Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corporation, British Columbia Cancer Agency Branch filed Critical Signalchem Lifesciences Corporation
Publication of HK1212389A1 publication Critical patent/HK1212389A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • G01N33/5758
    • G01N33/5759
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
HK15102061.3A 2011-10-24 2012-10-24 Carbonic anhydrase ix-related markers and use thereof HK1212389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550807P 2011-10-24 2011-10-24
US61/550,807 2011-10-24
PCT/US2012/061711 WO2013063130A1 (fr) 2011-10-24 2012-10-24 Marqueurs associés à l'anhydrase carbonique ix et leur utilisation

Publications (1)

Publication Number Publication Date
HK1212389A1 true HK1212389A1 (en) 2016-06-10

Family

ID=47356277

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102061.3A HK1212389A1 (en) 2011-10-24 2012-10-24 Carbonic anhydrase ix-related markers and use thereof

Country Status (7)

Country Link
US (1) US10195174B2 (fr)
EP (1) EP2771488B1 (fr)
JP (1) JP6259764B2 (fr)
CN (1) CN104136629B (fr)
CA (1) CA2853283C (fr)
HK (1) HK1212389A1 (fr)
WO (1) WO2013063130A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6683986B2 (ja) * 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
JP6277894B2 (ja) * 2014-07-08 2018-02-14 株式会社島津製作所 上皮間葉転換の有無を判別する方法
CN104630380B (zh) * 2015-03-06 2016-08-24 河北医科大学第四医院 碳酸酐酶iv在制备肺腺癌诊断制剂中的应用
CN107158388B (zh) * 2017-07-11 2021-03-23 上海市第一人民医院 MIIP pS303阻断剂在制备抗肿瘤药物中的应用
EP4031181A2 (fr) * 2019-09-18 2022-07-27 Biomarker Strategies, LLC. Procédés pour améliorer la réponse d'un patient à des inhibiteurs du point de contrôle immunitaire et tests fonctionnels pour prédire une réponse

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US20050048566A1 (en) * 2001-08-27 2005-03-03 Delisi Charles Apparatus, composition and method for proteome profiling
EP1461082A4 (fr) 2001-12-03 2006-06-28 Abgenix Inc Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
CA2691447A1 (fr) 2002-11-26 2004-06-10 Institute Of Virology Inhibiteurs specifiques de ca ix
AU2005308594A1 (en) 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnosis of prostate cancer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US9353415B2 (en) 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
US20080255243A1 (en) 2007-04-13 2008-10-16 Petricoin Emanuel F Stat3 as a theranostic indicator
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US20090123439A1 (en) * 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
JP2010178650A (ja) * 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
US20100317533A1 (en) * 2009-06-05 2010-12-16 British Columbia Cancer Agency Branch Biomarkers of cancer metastasis
CA3256492A1 (en) * 2010-01-11 2025-11-29 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2012021963A1 (fr) 2010-07-09 2012-02-23 Metasignal Therapeutics Inc. Nouveaux composés de sulfonamide destinés à l'inhibition de la croissance tumorale métastatique

Also Published As

Publication number Publication date
EP2771488A1 (fr) 2014-09-03
CN104136629B (zh) 2021-08-24
US10195174B2 (en) 2019-02-05
CA2853283C (fr) 2022-04-26
CN104136629A (zh) 2014-11-05
EP2771488B1 (fr) 2018-03-28
JP6259764B2 (ja) 2018-01-10
CA2853283A1 (fr) 2013-05-02
WO2013063130A1 (fr) 2013-05-02
US20140303103A1 (en) 2014-10-09
JP2014532864A (ja) 2014-12-08

Similar Documents

Publication Publication Date Title
WO2013009655A3 (fr) Utilisations d'inhibiteurs marqués de hsp90
BR112014002616A2 (pt) método para detectar cãncer pancreático e reagente ou kit para detectar câncer pancreático
WO2012106718A3 (fr) Procédés d'utilisation de signatures d'expression génique pour sélectionner un procédé de traitement, prédire un pronostic, la survie, et/ou prédire une réponse à un traitement
PH12013502340A1 (en) Biomarkers for hedgehog inhibitor therapy
DK2438446T3 (da) Fremgangsmåder, reagenser og kits til flowcytometrisk immunfænotypebestemmelse
ZA201402627B (en) Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
EP2274617A4 (fr) Procédés d identification et utilisation d agents ciblant les cellules souches cancéreuses
WO2014071358A3 (fr) Nouvelles molécules de fusion de ntrk1 et leurs utilisations
WO2012096545A3 (fr) Nouveau biomarqueur du cancer du pancréas utilisant les caractéristiques des cellules souches du cancer du pancréas, et son utilisation
WO2013066369A3 (fr) Procédés de détection de maladie du greffon contre l'hôte
IL217030A (en) Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
WO2013022786A3 (fr) Biomarqueurs micro-arn
WO2012082470A3 (fr) Utilisation d'anticorps anti-cxcl16 et anti-cxcr6 pour le traitement ou la détection du cancer
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
EA201201526A1 (ru) Способы лечения состояний, связанных с il-1b
WO2012135749A3 (fr) Marqueurs biologiques pour prévoir la sensibilité à des traitements du cancer
HK1212389A1 (en) Carbonic anhydrase ix-related markers and use thereof
EP2757154A4 (fr) Procédé de détection de cellules cancéreuses vésicales, amorce utilisée dans ledit procédé, et marqueur du cancer de la vessie
WO2012019000A3 (fr) Biomarqueurs pour l'identification, la surveillance et le traitement du cancer de l'ovaire
WO2012164525A3 (fr) Biomarqueurs de vieillissement
WO2013124738A3 (fr) Méthodes et biomarqueurs permettant de dépister et de pronostiquer le cancer du col utérin
EP2691776A4 (fr) Marqueurs pour l'identification de cellules tumorales, procédés et trousse correspondants
WO2012145516A3 (fr) Procédés et kits de détermination quantitative de la teneur totale en acides organiques dans un agent de refroidissement